Global Markets Direct’s, 'Pharyngitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pharyngitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pharyngitis. Pharyngitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Pharyngitis. - A review of the Pharyngitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pharyngitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Pharyngitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pharyngitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Pharyngitis - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Pharyngitis Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Pharyngitis 6 Pharyngitis Therapeutics under Development by Companies 8 Late Stage Products 9 Comparative Analysis 9 Pharyngitis Therapeutics - Products under Development by Companies 10 Companies Involved in Pharyngitis Therapeutics Development 11 Zambon Group S.p.A. 11 BioStar Pharmaceuticals, Inc. 12 Pharyngitis - Therapeutics Assessment 13 Assessment by Monotherapy Products 13 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Drug Profiles 18 azithromycin - Drug Profile 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 Pharyngitis Therapeutics - Dormant Products 19 Pharyngitis - Product Development Milestones 20 Featured News and Press Releases 20 Mar 17, 2010: MiddleBrook Pharmaceuticals Announces Expanded Increase Rx Promotion for Moxatag 20 Feb 03, 2010: MiddleBrook Announces Promotion Partnership Of MOXATAG Tablets With DoctorDirectory.com For The Treatment Of Tonsillitis And Pharyngitis 20 Feb 03, 2010: MiddleBrook Pharmaceuticals Announces Promotion Partnership with DoctorDirectory.com for Moxatag (extended-release amoxicillin) Tablets, 775mg 20 Oct 12, 2009: Moxatag Supports Health Education on FamilyDoctor.org 21 Jul 15, 2009: MiddleBrook Pharmaceuticals Announces $20 Maximum Copay Program for Moxatag 21 May 01, 2009: MiddleBrook Pharmaceuticals Launches Moxatag Website, Announces Early Prescription Data for Moxatag 22 Mar 16, 2009: MiddleBrook Pharmaceuticals Launches Moxatag, the First and Only FDA-Approved Once-Daily Amoxicillin 22 Feb 04, 2009: MiddleBrook Pharmaceuticals Retains Almac Pharma Services to Produce Physician Samples of Moxatag 23 Jan 07, 2009: MiddleBrook Pharmaceuticals to Launch Moxatag March 2009 23 Nov 06, 2008: MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag Patents 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables
Number of Products Under Development for Pharyngitis, H1 2013 6 Products under Development for Pharyngitis - Comparative Analysis, H1 2013 7 Number of Products under Development by Companies, H1 2013 8 Comparative Analysis by Late Stage Development, H1 2013 9 Products under Development by Companies, H1 2013 10 Zambon Group S.p.A., H1 2013 11 BioStar Pharmaceuticals, Inc., H1 2013 12 Assessment by Monotherapy Products, H1 2013 13 Assessment by Stage and Route of Administration, H1 2013 15 Assessment by Stage and Molecule Type, H1 2013 17 Pharyngitis Therapeutics - Dormant Products 19
List of Figures
Number of Products under Development for Pharyngitis, H1 2013 6 Products under Development for Pharyngitis - Comparative Analysis, H1 2013 7 Products under Development by Companies, H1 2013 8 Late Stage Products, H1 2013 9 Assessment by Monotherapy Products, H1 2013 13 Assessment by Route of Administration, H1 2013 14 Assessment by Stage and Route of Administration, H1 2013 15 Assessment by Molecule Type, H1 2013 16 Assessment by Stage and Molecule Type, H1 2013 17